Wall Street brokerages predict that Arcadia Biosciences Inc (NASDAQ:RKDA) will report earnings of ($0.61) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Arcadia Biosciences’ earnings. The highest EPS estimate is ($0.51) and the lowest is ($0.70). Arcadia Biosciences reported earnings of ($0.96) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 36.5%. The business is scheduled to report its next quarterly earnings report on Wednesday, August 12th.
According to Zacks, analysts expect that Arcadia Biosciences will report full year earnings of ($1.19) per share for the current financial year, with EPS estimates ranging from ($1.54) to ($0.84). For the next financial year, analysts expect that the firm will post earnings of ($0.97) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Arcadia Biosciences.
Arcadia Biosciences (NASDAQ:RKDA) last announced its quarterly earnings results on Wednesday, May 13th. The basic materials company reported $0.29 EPS for the quarter, beating the consensus estimate of ($0.55) by $0.84. Arcadia Biosciences had a negative net margin of 1,035.38% and a negative return on equity of 180.70%. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.60 million.
A number of institutional investors have recently made changes to their positions in the business. Oxford Asset Management LLP acquired a new position in Arcadia Biosciences during the 4th quarter worth about $191,000. Wells Fargo & Company MN lifted its position in Arcadia Biosciences by 263.2% during the 1st quarter. Wells Fargo & Company MN now owns 16,343 shares of the basic materials company’s stock valued at $46,000 after purchasing an additional 11,843 shares during the period. Virtu Financial LLC acquired a new position in Arcadia Biosciences during the 4th quarter valued at about $61,000. Geode Capital Management LLC lifted its position in Arcadia Biosciences by 21.3% during the 4th quarter. Geode Capital Management LLC now owns 38,223 shares of the basic materials company’s stock valued at $209,000 after purchasing an additional 6,708 shares during the period. Finally, Morgan Stanley lifted its position in Arcadia Biosciences by 28.2% during the 1st quarter. Morgan Stanley now owns 13,878 shares of the basic materials company’s stock valued at $40,000 after purchasing an additional 3,052 shares during the period. 5.07% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:RKDA traded down $0.03 during trading hours on Friday, hitting $4.08. The stock had a trading volume of 142,995 shares, compared to its average volume of 327,139. The stock’s fifty day simple moving average is $4.03 and its 200 day simple moving average is $4.34. Arcadia Biosciences has a 1-year low of $1.82 and a 1-year high of $10.20. The firm has a market capitalization of $35.57 million, a price-to-earnings ratio of -2.50 and a beta of -0.72. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.06 and a current ratio of 4.09.
About Arcadia Biosciences
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.
Read More: Example of operating income, EBIT and EBITDA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.